Peter Olof Sjö

Dr. Peter Olof Sjö

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
GNGabriela Dias Noske
Gabriela Dias Noske
ESEllen de Souza Silva
Ellen de Souza Silva
MGMariana Ortiz de Godoy
Mariana Ortiz de Godoy
IDIsabela Dolci
Isabela Dolci
RFRafaela Sachetto Fernandes
Rafaela Sachetto Fernandes
AGAndre Godoy
Andre Godoy
SARS-CoV-2 is the causative agent of COVID-19. The main viral protease (Mpro) is an attractive target for antivirals. The clinically approved drug nirmatrelvir and the clinical candidate ensitrelvir have so far showed great potential for treatment of viral infection. However, the broad use of antivirals is often associated with resistance generation. Herein, we enzymatically characterized 14 naturally occurring Mpro polymorphisms that are close to the binding site of these antivirals. Nirmatrelvir retained its potency against most polymorphisms tested, while mutants G143S and Q189K were associated with diminished inhibition constants. For ensitrelvir, diminished inhibition constants were observed for polymorphisms M49I, G143S, and R188S, but not for Q189K, suggesting a distinct resistance profile between inhibitors. In addition, the crystal structures of selected polymorphisms revealed interactions that were critical for loss of potency. In conclusion, our data will assist the monitoring of potential resistant strains, support the design of combined therapy, as well as assist the development of the next generation of Mpro inhibitors.

15 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
RARana Abdelnabi
Rana Abdelnabi
CFCaroline Shi-Yan Foo
Caroline Shi-Yan Foo
DJDIRK JOCHMANS
DIRK JOCHMANS
LVLaura Vangeel
Laura Vangeel
SJSteven De Jonghe
Steven De Jonghe
JNJohan Hendrik Neyts
Johan Hendrik Neyts
There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.

15 December 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
NMNeelika Malavige
Neelika Malavige
PSPeter Olof Sjö
Peter Olof Sjö
KSKavita Singh
Kavita Singh
JPJean-Michel Piedagnel
Jean-Michel Piedagnel
CMCharles Mowbray
Charles Mowbray
IRIsabela Ribeiro
Isabela Ribeiro
Dengue is the most rapidly emerging mosquito-borne infection and, due to climate change and unplanned urbanization, it is predicted that the global burden of dengue will rise further as the infection spreads to new geographical locations. Dengue-endemic countries are often unable to cope with such increases, with health care facilities becoming overwhelmed during each dengue season. Furthermore, although dengue has been predominantly a childhood illness in the past, it currently mostly affects adults in many countries, with higher incidence of severe disease and mortality rates in pregnant women and in those with comorbidities. As there is currently no specific treatment for dengue and no early biomarker to identify those who will progress to develop vascular leakage, all individuals with dengue are closely monitored in case they need fluid management. Furthermore, diagnosing patients with acute dengue is challenging due to the similarity of clinical symptoms during early illness and poor sensitivity and specificity of point-of-care diagnostic tests. Novel vector control methods, such as the release of Wolbachia-infected mosquitoes, have shown promising results by reducing vector density and dengue incidence in clinical trial settings. A new dengue vaccine, TAK-003, had an efficacy of 61.2% against virologically confirmed dengue, 84.1% efficacy against hospitalizations and a 70% efficacy against development of dengue haemorrhagic fever (DHF) at 54 months. While vaccines and mosquito control methods are welcome, they alone are unlikely to fully reduce the burden of dengue, and a treatment for dengue is therefore essential. Several novel antiviral drugs are currently being evaluated along with drugs that inhibit host mediators, such as mast cell products. Although viral proteins such as NS1 contribute to the vascular leak observed in severe dengue, the host immune response to the viral infection also plays a significant role in progression to severe disease. There is an urgent need to discover safe and effective treatments for dengue to prevent disease progression.

6 September 2011 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ISIgor Shamovsky
Igor Shamovsky
LRLena Ripa
Lena Ripa
LBLena Börjesson
Lena Börjesson
CMChristine Mee
Christine Mee
BNBo Nordén
Bo Nordén
PSPeter Olof Sjö
Peter Olof Sjö

1 June 1992 in Tetrahedron Letters
Verified
Journal Article
Closed access
KJKyu-Sung Jeong
Kyu-Sung Jeong
PSPeter Olof Sjö
Peter Olof Sjö
KSK.Barry Sharpless
K.Barry Sharpless

29 March 2012 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
PSPeter Olof Sjö
Peter Olof Sjö
Due to its implication in pathologies of prevalent diseases such as chronic obstructive pulmonary disease, fibrosis, bronchiectasis and ARDS, the serine protease, human neutrophil elastase, has been in focus for drug-development efforts over the last two decades. In recent years, continued efforts to identify and optimize novel mechanism-based inhibitors have led to a number of new inhibitors being reported. These compounds show promising potency and selectivity profiles, although their use is still limited by their inherent stability. Recently, two novel classes of potent and selective, synthetic, nonelectrophilic human neutrophil elastase inhibitors that display improved stability and overall drug-like properties have been reported. The most advanced compound from these classes, AZD9668, has been reported to show significant effects on relevant biomarkers in bronchiectasis and cystic fibrosis patient populations.